The TRIUMPH Phase 3 program The TRIUMPH program consists of multiple Phase 3 trials evaluating retatrutide in different populations
Here, we have used glucagon-like peptide-1 (GLP-1) as a model peptide therapeutic for treating obesity-linked type 2 diabetes, a common chronic disease
Morales says that sometimes people accuse her of only promoting products, including the patches, to make money
In metabolic research, common readouts include body mass change, food intake, circulating biomarkers, adipose depot measurements, and indirect markers of substrate handling and energy use
PARP inhibition: PARP1 and beyond
The company will aim to rely more on GLP-1 drugs that have been specifically approved for obesity like Wegovy, she said